Comparative Analysis of Serum Leptin and Adiponectin Levels in Obese and Non-Obese Individuals and their Association with Cardiovascular Risk
DOI:
https://doi.org/10.63682/jns.v14i32S.10242Keywords:
Leptin, Adiponectin, Obesity, Cardiovascular Risk, Adipokines, DyslipidemiaAbstract
Background: Obesity is a major global health concern strongly associated with cardiovascular diseases (CVD). Adipokines, particularly leptin and adiponectin, play crucial roles in energy homeostasis, inflammation, and vascular function. Alterations in these biomarkers may contribute to increased cardiovascular risk.
Objective: To compare serum leptin and adiponectin levels in obese and non-obese individuals and evaluate their association with cardiovascular risk factors.
Methods: A comparative cross-sectional study was conducted on 120 participants (60 obese, 60 non-obese). Serum leptin and adiponectin were measured by ELISA. Cardiovascular parameters were assessed and analyzed using SPSS.
Results: Mean serum leptin levels were significantly higher in obese individuals (32.8 ± 8.6 ng/mL) compared to non-obese (11.4 ± 4.2 ng/mL; p<0.001). Mean adiponectin levels were significantly lower in obese individuals (4.6 ± 1.5 µg/mL) compared to non-obese (9.8 ± 2.7 µg/mL; p<0.001). Obese participants had higher BMI (31.9 ± 2.8 vs 22.6 ± 1.9 kg/m²), systolic BP (138.5 ± 12.4 vs 118.2 ± 9.6 mmHg), and LDL levels (142.6 ± 28.3 vs 104.7 ± 22.5 mg/dL). Leptin showed strong positive correlation with BMI (r=0.72) and LDL (r=0.61), while adiponectin showed negative correlation with BMI (r=−0.68) and positive correlation with HDL (r=0.55) (p<0.001).
Conclusion: Elevated leptin and reduced adiponectin are significantly associated with increased cardiovascular risk in obese individuals..
Downloads
References
World Health Organization. Obesity and overweight. Geneva: WHO; 2023.
2. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ. Obesity and cardiovascular disease: a scientific statement. Circulation. 2021;143(21):e984–e1010.
3. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2021;39(3):223–236.
4. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2022;18(3):143–156.
5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2021;21(2):85–97.
6. Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab. 2022;4(3):273–285.
7. Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance. Cell Metab. 2021;33(3):427–438.
8. Liu M, Liu F. Adiponectin and metabolic diseases. Endocrinology. 2022;163(2):bqac001.
9. Yamauchi T, Kadowaki T. Adiponectin receptor signaling in metabolic regulation. J Clin Invest. 2021;131(1):e143803.
10. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: a biomarker of adipose tissue dysfunction. Nutrients. 2021;13(8):2582.
11. Packer M. Leptin-aldosterone-neprilysin axis in obesity. Eur Heart J. 2021;42(30):2909–2911.
12. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of cardiovascular disease. Nat Rev Cardiol. 2022;19(4):235–250.
13. Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2021;9(9):616–627.
14. Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity. Circulation. 2021;143(7):699–713.
15. Wannamethee SG, Atkins JL. Adipokines and cardiovascular disease. Heart. 2022;108(5):345–352.
16. López-Jaramillo P, Gómez-Arbeláez D, López-López J. Adipose tissue dysfunction and cardiometabolic risk. J Am Coll Cardiol. 2021;77(7):853–867.
17. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2021;30(2):135–141.
18. Hall JE, do Carmo JM, da Silva AA. Obesity-induced hypertension. Hypertension. 2021;77(3):e1–e12.
19. Martín SS, Qasim AN, Reilly MP. Leptin resistance and cardiovascular risk. Curr Cardiol Rep. 2021;23(5):45.
20. Fang H, Judd RL. Adiponectin regulation and function. Cell Mol Life Sci. 2021;78(6):1–15.
21. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health. Br J Pharmacol. 2022;179(2):1–12.
22. Achari AE, Jain SK. Adiponectin, metabolic syndrome, and cardiovascular disease. J Diabetes Complications. 2022;36(3):108163.
23. Frühbeck G, Catalán V. Adipokine imbalance in obesity. Int J Obes. 2023;47(1):1–10.
24. Kadowaki T, Yamauchi T. Adiponectin and metabolic syndrome. Endocr Rev. 2021;42(2):1–17.
25. Rodríguez A, Becerril S, Ezquerro S. Crosstalk between adipokines and cardiometabolic risk. Front Endocrinol. 2022;13:865488..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
